Comprehensive, Rigorous Prep for MCAT Physics.

The MCAT Physics Book offers the most comprehensive and rigorous analysis of MCAT physics available. Including,

* 49 MCAT-style passages

* 500 MCAT-style practice problems and detailed solutions to all problems.

Illustrations and tables are included wherever necessary to focus and clarify key ideas and concepts.

Dr. Biehle's classic MCAT Physics Book presents a clear, insightful analysis of MCAT physics. His lively prose and subtle wit make this challenging topic more palatable.

Dr. Biehle received his Ph.D. from Caltech (California Institute of Technology) in physics. He has ten years experience at various levels in science education. The MCAT Physics Book is a result of his experience presenting physics concepts in a classroom setting to students preparing for the MCAT.

Preparing a learning portfolio has become a mandatory part of the course work in most clinical professions. Students and educators alike sometimes complain that these mandatory assignments become repetitive and uninspired. However, we all need to be able to speak and write clearly as we work with our colleagues, students and those we care for. In Portfolio To Go, Allan D. Peterkin insists that reflective capacity, critical thinking, creative expression, and narrative competence are attributes that should be developed in every health professional - regardless of the discipline or specialty. Trainees will find over 1000 prompts organized under themes highly relevant to students and educators, including those not formally addressed in class, such as coping with uncertainty and ambiguity, team conflict, and resilience through good self-care. Practical tips for writing effectively and for discussing and evaluating narratives in a helpful, respective manner are provided throughout. Peterkin is a pioneer in emphasizing patient-centred, humanistic care and Portfolio To Go will help to train and develop more reflective practitioners.

We have collected precise clinically relevant information from valid open access resources, and presented it in a Unique "color-coded and typographically spaced" format designed to reinforce "Visual memorization" and recall of important clinical information, as and when needed. We have avoided memory clutter by including only the relevant "Take Home" pearls designed to sharpen evidence-based clinical decision making skills. Medicine is an ever-changing subject. Information presented in this book is solely intended as a memory aid. This information should not be used to cure, diagnose or treat any medical condition or symptoms.

The Manual for the Surveillance of Vaccine-Preventable Diseases, updated through 2013, provides current guidelines for those directly involved in surveillance of vaccine-preventable diseases, especially personnel at the local health departments. For each of the vaccine-preventable diseases, this manual includes a chapter describing the importance of rapid case identification; the importance of surveillance; disease reduction goals; case definitions (including clinical description and case classifications); epidemiologically important data to be collected during case investigation; activities for enhancing surveillance; activities for case investigation; and activities for outbreak control. Other chapters include information on surveillance indicators; surveillance data analyses; reporting adverse events following vaccination; and enhancing surveillance. In addition, the manual includes a section reserved for insertion of state-specific guidance for VPD surveillance and extensive appendices. This manual was first developed in 1996 to provide general guidance to state and local health department personnel who are involved in surveillance activities for vaccine-preventable diseases. This manual answers commonly asked questions regarding the surveillance and reporting of vaccine-preventable diseases and provides information on enhancing existing surveillance systems.

Regenerative medicine holds the potential to create living, functional cells and tissues that can be used to repair or replace those that have suffered potentially irreparable damage due to disease, age, traumatic injury, or genetic and congenital defects. The field of regenerative medicine is broad and includes research and development components of gene and cell therapies, tissue engineering, and non-biologic constructs. Although regenerative medicine has the potential to improve health and deliver economic benefits, this relatively new field faces challenges to developing policies and procedures to support the development of novel therapies are both safe and effective. In October 2016, the National Academies of Sciences, Engineering, and Medicine hosted a public workshop with the goal of developing a broad understanding of the opportunities and challenges associated with regenerative medicine cellular therapies and related technologies. Participants explored the state of the science of cell-based regenerative therapies within the larger context of patient care and policy. This publication summarizes the presentations and discussions from the workshop. Table of Contents Front Matter 1 Introduction 2 Skin and Musculoskeletal Tissues 3 Hematologic and Immunologic Applications 4 Neurological and Ophthalmological Tissues 5 Cardiovascular and Lung Tissues 6 Renal Tissue 7 Looking Toward the Future: Concluding Thoughts References Appendix A: Workshop Agenda Appendix B: Speaker Biographical Sketches Appendix C: Statement of Task Appendix D: Registered Attendees

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop. Table of Contents Front Matter 1 Introduction and Overview 2 Drug Development for Nervous System Disorders: Overview of Challenges and Potential Opportunities 3 Case Studies: Therapeutic Development for Parkinson's Disease and Schizophrenia in the Absence of Predictive Animal Models of Disease 4 New Modeling Approaches for Nervous System Disorders 5 Private-Sector Thresholds for Investment in Neuroscience Clinical Trials 6 Ethical Considerations 7 Regulatory Perspectives Appendix A: References Appendix B: Workshop Agenda Appendix C: Registered Attendees